VTCN1 Human, Sf9
Sf9, Baculovirus cells.
V-set domain-containing T-cell activation inhibitor 1, B7 homolog 4, B7-H4, B7h.5, Immune costimulatory protein B7-H4, Protein B7S1, T-cell costimulatory molecule B7x, B7H4, VTCN1, B7S1, B7X, PRO1291, RP11-229A19.4.
Greater than 90.0% as determined by SDS-PAGE.
Description
VTCN1 Human Recombinant produced in Sf9 Baculovirus cells is a single, glycosylated polypeptide chain containing 244 amino acids (25-259a.a.) and having a molecular mass of 26.9kDa (Molecular size on SDS-PAGE will appear at approximately 28-40kDa). VTCN1 is expressed with a 9 amino acids His tag at C-Terminus and purified by proprietary chromatographic techniques.
Product Specs
V-set domain-containing T-cell activation inhibitor 1, B7 homolog 4, B7-H4, B7h.5, Immune costimulatory protein B7-H4, Protein B7S1, T-cell costimulatory molecule B7x, B7H4, VTCN1, B7S1, B7X, PRO1291, RP11-229A19.4.
Sf9, Baculovirus cells.
ADPLIIGFGI SGRHSITVTT VASAGNIGED GILSCTFEPD IKLSDIVIQW LKEGVLGLVH EFKEGKDELS EQDEMFRGRT AVFADQVIVG NASLRLKNVQ LTDAGTYKCY IITSKGKGNA NLEYKTGAFS MPEVNVDYNA SSETLRCEAP RWFPQPTVVW ASQVDQGANF SEVSNTSFEL NSENVTMKVV SVLYNVTINN TYSCMIENDI AKATGDIKVT ESEIKRRSHL QLLNSKASHH HHHH.
Product Science Overview
The V-Set Domain Containing T Cell Activation Inhibitor 1 (VTCN1), also known as B7-H4, B7S1, and B7x, is a protein that plays a crucial role in the immune system. It is a member of the B7 family of immune regulatory proteins, which are known for their roles in modulating immune responses. VTCN1 is particularly significant for its inhibitory effects on T cell activation, making it a key player in immune regulation and a potential target for therapeutic interventions in various diseases, including cancer and autoimmune disorders .
VTCN1 is a type 1 transmembrane protein that contains a V-set domain, which is characteristic of the immunoglobulin superfamily. This protein is highly glycosylated and is expressed on the surface of antigen-presenting cells (APCs) such as macrophages and dendritic cells . The expression of VTCN1 is also observed in various tumor cells, where it contributes to the suppression of anti-tumor immune responses .
The primary function of VTCN1 is to negatively regulate T cell-mediated immune responses. It achieves this by inhibiting T cell activation, proliferation, cytokine production, and the development of cytotoxicity . When expressed on tumor-associated macrophages, VTCN1 plays a significant role in the suppression of tumor-specific T cell immunity, thereby promoting tumor progression .
VTCN1 has been implicated in various diseases, particularly in cancer and autoimmune disorders. In cancer, high levels of VTCN1 expression are often associated with tumor progression and poor prognosis . This is because VTCN1 helps tumors evade the immune system by inhibiting the activation and function of T cells that would otherwise target and destroy cancer cells . In autoimmune diseases, VTCN1’s role in dampening immune responses can be beneficial, as it may help reduce the overactive immune responses that characterize these conditions .
Given its significant role in immune regulation, VTCN1 is a potential target for therapeutic interventions. In cancer therapy, strategies to block VTCN1 function could enhance anti-tumor immune responses and improve the efficacy of immunotherapies . Conversely, in autoimmune diseases, enhancing VTCN1 activity could help suppress harmful immune responses and alleviate disease symptoms .
